XMT 1107

Drug Profile

XMT 1107

Alternative Names: XMT-1107; XMT-1191

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Mersana Therapeutics
  • Class Antineoplastics; Drug conjugates; Polymers
  • Mechanism of Action Methionine aminopeptidase 2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Solid tumours

Most Recent Events

  • 09 Mar 2017 Mersana Therapeutics has patent protection for Fleximer-ADC platform technology in the European Union
  • 03 Jun 2014 Mersana Therapeutics completes a phase I trial in Solid tumours (Late-stage disease, Second-line therapy or greater) in the US (NCT01011972)
  • 15 May 2013 Mersana Therapeutics completes enrolment in its phase I trial for Solid tumours (Late-stage disease, Second-line therapy or greater) in the US (NCT01011972)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top